Rich Pharmaceuticals is committed to developing new therapies to treat life-threatening diseases. Among the most important steps in this process are the clinical trials, where patients offer to receive an experimental new drug and be monitored for its effects.
Results from clinical trials are submitted for review to the U.S. Food and Drug Administration (FDA), which establish safety and efficacy standards for medical products. If a medicine meets these standards, it can be approved and becomes available by prescription.
If you are a patient looking for information about clinical trials, please click here
If you are a medical professional looking for information about clinical trials, please visit the Clinical Trials section of www.RichPharmaceuticals.com for Medical Professionals.
The National Institutes of Health offers up-to-date information on clinical trials for a wide range of diseases and conditions at www.clinicaltrials.gov
Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin’s Lymphoma
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy